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Abstract
Background: Cirrhotic patients are characterized by a decreased synthesis of coagulation and anticoagulation
factors. The coagulopathy of cirrhotic patients is considered to be auto-anticoagulation. Our aim was to determine
the incidence and predictors of venous thromboembolism (VTE) and examine the practice of deep venous
thrombosis (DVT) prophylaxis among hospitalized cirrhotic patients.
Methods: A retrospective cohort study was performed in a tertiary teaching hospital. We included all adult
patients admitted to the hospital with a diagnosis of liver cirrhosis from January 1, 2009 to December 31, 2009. We
grouped our cohort patients in two groups, cirrhotic patients without VTE and cirrhotic with VTE.
Results: Over one year, we included 226 cirrhotic patients, and the characteristics of both groups were similar
regarding their clinical and laboratory parameters and their outcomes. Six patients (2.7%) developed VTE, and all of
the VTEs were DVT. Hepatitis C was the most common (51%) underlying cause of liver cirrhosis, followed by
hepatitis B (22%); 76% of the cirrhotic patients received neither pharmacological nor mechanical DVT prophylaxis.
Conclusion: Cirrhotic patients are at risk for developing VTE. The utilization of DVT prophylaxis was suboptimal.
Introduction
Liver cirrhosis is a major health problem worldwide,
especially in Saudi Arabia [1] where the prevalence of
liver cirrhosis is not precisely known but is expected to
be high due to the relatively high prevalence of viral
hepatitis [2-4]. Liver cirrhosis is accompanied by multiple
changes in the hemostatic system due to the reduced
levels of natural inhibitors of coagulation and coagulation
factors because of the impaired hepatic synthetic activity
[5]. Thus, the global effect of liver disease on hemostasis
is complex, and therefore, patients with liver cirrhosis
can experience bleeding or thrombotic complications [6].
The pathogenesis of venous thromboembolism (VTE) in
cirrhosis is complex and involves several factors, both
endogenous changes associated with cirrhosis with
increased levels of factors VII and also protein C activity
is limited in the absence of the endothelial receptor
thrombomodulin and therefore it cannot exert its full
anti-coagulant activity as well as external factors, one of
which is limited physical activity due to the disease itself
[7-10]. The incidence of VTE among high-risk hospita-
lized patients has been reported to range between 4 and
12% [7]. In a large necropsy series, in which fatal VTE
accounted for 7-10% of all hospital-related deaths, 70-
90% of the patients had no premorbid symptoms [11].
Among these subjects with VTE, approximately 25% died
within 7 days of VTE onset [12]. In addition, the Ameri-
can College of Chest Physicians (ACCP) guidelines on
VTE prophylaxis do not specifically address patients with
coagulopathy due to liver cirrhosis [13]. Based on the
presence of coagulopathy in cirrhotic patients, these
patients are considered to be auto-anticoagulant [14].
Hence, the institution of deep vein thrombosis (DVT)
prophylaxis in cirrhotic patients may not be a standard
practice, and the use of DVT prophylaxis in this patient
population is expected to be variable.
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the incidence and predictors of VTE and to examine the
practice of DVT prophylaxis among hospitalized cirrho-
tic patients.
Methods
Study population
A retrospective chart review was conducted of patients
with discharge ICD-9 diagnosis codes corresponding to
liver cirrhosis who were admitted to a tertiary care hos-
pital in Riyadh, Saudi Arabia, from January 1, 2009 to
December 31, 2009. These patients were adults of
18 years or older and had a history and clinical presen-
tation consistent with liver cirrhosis and/or a liver
biopsy showing cirrhosis. Patients on anticoagulation
t h e r a p yw e r ee x c l u d e df r o mt h es t u d y .T h es t u d yw a s
approved by King Abdullah International Medical
Research Center and the institutional review board of
the hospital (IRB). The approval allowed for a retrospec-
tive chart review without informed consent.
Data collection
For each patient, the following information was col-
lected: age, gender, admission creatinine, international
normalized ratio (INR), bilirubin, albumin and platelet
counts, etiology of liver cirrhosis (viral hepatitis, alcohol,
autoimmune, cryptogenic), Child-Pugh score, VTE risk
factors (history of malignancy, prior VTE, hormonal
replacement therapy, oral contraceptives), use of phar-
macologic prophylaxis in the form of unfractionated
heparin (UFH) or low molecular-weight heparin
(LMWH) and the use of mechanical prophylaxis.
Patients were followed up until discharge from the hos-
pital or until death, whichever was earlier.
Outcome measures
The primary outcome was defined as the development
of symptomatic DVT or PE, as confirmed by venous
Doppler ultrasound (VD-US) of the lower limbs,
spiral CT of the chest or a high probability ventilation-
perfusion (VQ) scan. These tests were ordered by the
treating physician based on clinical suspicion. The sec-
ondary outcome was the use of DVT prophylaxis.
Statistical analysis
Continuous data were compared using the Kruskal-Wallis
test and are expressed as the median and Interquartile
range according to normality testing using Kolmogorov-
Smirnov test. Categorical data were compared using the
chi-square test or Fisher’s exact test and are expressed as
a percentage. Statistical significance was defined as alpha
less than 0.05. Statistical analysis was performed using
Minitab for Windows (release 13.1).
Results
General characteristics
During the study period, 226 patients were admitted to
the hospital with liver cirrhosis. Only six (2.7%) patients
were diagnosed with VTE. Table 1 summarizes the char-
acteristics of the cirrhotic patients without VTE (n =
220) and with VTE (n = 6). Both groups were similar
with respect to baseline characteristics, including admis-
sion albumin, bilirubin, creatinine and coagulation pro-
file. Hepatitis C accounted for 115 (51%) of the liver
cirrhosis cases, followed by hepatitis B accounting for 49
cases (22%) and uncommon causes such as cryptogenic,
autoimmune or alcohol. However, the etiology of liver
cirrhosis and the prevalence of hepatocellular carcinoma
were similar in both groups. Infection was the most
common cause of hospital admission in this group of
patients (53.5%), followed by bleeding (23.8%). The need
for intensive care unit(ICU) admission was similar in
both groups. There was a trend toward a higher Child-
Pugh score in cirrhotic patients with VTE.
Incidence and risk factors of VTE
Six patients (2.7%) developed DVT, which was identified
clinically and confirmed by VD-US. None of the cirrho-
tic patients developed pulmonary embolism; the spiral
C To ft h ec h e s tw a sd o n eo n l yo n c ea n dt u r n e dt ob e
negative. There was no statistically significant difference
in the incidence of VTE among the two groups based
on the reason of the admission to the hospital.
DVT was suspected in 18 (8%) cirrhotic patients and
was confirmed only in 6 (2.7%) patients. A previous his-
tory of VTE was higher in cirrhotic patients with VTE
(0 vs. 2), whereas the other VTE risks factors were simi-
lar in the two groups (Table 2).
Practices of VTE prophylaxis
Approximately 76% of the cirrhotic patients included in
the cohort received neither pharmacological nor
mechanical DVT prophylaxis (Table 3). Only four cir-
rhotic patients without VTE (1.8%) received LMWH. No
significant differences in the incidence of VTE were
observed between the group that received pharmacolo-
gic or mechanical prophylaxis and the group that did
not receive prophylaxis. Further, we carried out sub-
group analysis and found that there was no difference in
the use of prophylaxis in patients admitted due to infec-
tion, HCC and patients with high INR (>1.8) except
mechanical prophylaxis was used more in patients
admitted due to bleeding (P value 0.01).(table 3).
Discussion
The incidence of VTE was 2.7% in hospitalized cirrhotic
patients, where the VTE evaluations were performed
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Characteristic Cirrhotic patients with VTE Cirrhotic patients without VTE P value
Number (%) 6 (2.7%) 220 (97.3%)
Age in years*, 63.5(49-83.7) 63(54-70) 0.67
Sex 0.57
Male, N (%) 2 (33.3%) 138 (62.7%)
Female, N (%) 4 (66.6%) 82 (37.3%)
INR* 1.55(1.25-2.15) 1.3(1.1-1.6) 0.24
Patients admitted with INR≥ 1.8 1(16.6%) 40(18.2%) 1
APTT* 36.75 (29.3-38) 33(29-40) 0.75
Platelet count/μL* 201(122-265) 136(81-206) 0.12
Albumin (g/L)* 26.5(23.5-32.2) 30(26-35) 0.23
Bilirubin (μmol/L)* 28(14.7-209.4) 37.4(18-85.5) 0.88
Creatinine (μmol/L)* 93(87.5-138.6) 81(73-151) 0.49
Etiology of liver cirrhosis
Hepatitis B N (%)
2 (33.3%) 47 (21.3%) 0.6
Hepatitis C N (%) 3 (50.0%) 112 (50.9%) 1
Alcoholic N (%) 0 0
Autoimmune N (%) 0 4 (1.8%)
Cryptogenic N (%) 1 (16.6%) 46 (20.9%)
Other N (%) 0 16(7%)
Patients admitted with Infections 2 (33%) 119(54%) 0.42
Bleeding 2(33%) 52(23.6%) 0.63
Hepatocellular carcinoma N (%) 1 (16.6%) 100 (45.5%) 0.22
Incidence of ICU admission N (%) 2 (33.3%) 45 (20.5%) 0.6
Child-Pugh stage, mean ± SD 10.3 ± 1.97 8.25 ± 2.57 0.052
Grade A N (%) 0 70 (31.8%)
Grade B N (%) 3 (50%) 84 (38.2%) 0.68
Grade C N (%) 3 (50%) 72 (32.7%) 0.4
Hospital LOS*, 43(12.3-75.5) 8(4.25-14.7) 0.004
Hospital mortality N (%) 4 (66.6%) 73 (33.2%) 0.18
* Expressed as Median (Interquartile range).
INR: international normalized ratio.
APPT: activated partial thromboplastin time.
LOS: length of stay.
Table 2 Risk factors for venous thromboembolism (VTE) among cirrhotic patients
VTE risk factors Cirrhotic patients with VTE N = 6 Cirrhotic patients without VTE N = 220 P value
History of DVT 2 (33.3%) 0 (0%)
Post-operative 0 6 (2.7%)
Bedridden 0 7 (3.2%)
History of malignancy 0 5 (2.3%)
Femoral central line 1 (16.7%) 30 (13.6%) 0.57
IJ &SC central line 1 (16.7%) 35 (15.9%) 1
Diabetes mellitus 4 (66.7%) 91 (41.3%) 0.24
Values are expressed as numbers and percentages.
IJ: internal jugular, SC: subclavian.
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(76.1%) received neither pharmacological nor mechani-
cal DVT prophylaxis. The underlying coagulopathy
observed in cirrhotic patients has led to the notion that
these patients might be at a lower risk for VTE [7,15].
This hypothesis was suggested in a population-based
case-control study [12] performed in the last century,
which found that serious liver disease was associated
with a 90% reduction in the risk for VTE. However, that
s t u d yl a c k e dt h ed a t ao nt h es e v e r i t yo ft h el i v e rd i s -
eases, use of DVT prophylaxis, and the diagnosis of
VTE was not performed using the standard practices
[12]. However, the specific insight is inconsistent with
the results of many studies that have addressed the inci-
dence of VTE in cirrhotic patients. Recently a Danish
nationwide population- base case- control study [9]
showed that the liver cirrhosis was associated with
increased relative risk of VTE; 1.74 (95% CI,1.54-1.95)
and in patients with unprovoked VTE, relative risk was
slightly higher; 2.06(95% CI,1.79-2.38, regardless of the
presence of other risk factors. A case-control study [16]
showed that the prevalence of DVT in cirrhotic patients
was 4.7% and that diabetes mellitus was an independent
risk factor for the development of DVT, which were not
found in the present study. Northup et al. [17]conducted
a retrospective cohort study over an 8-year period and
determined an incidence of VTE among 21,000 cirrhotic
patients (in whom alcohol was the most frequent under-
lying etiology) of 0.5%, which had lower incidence of
VTE (4 to 12%) found in selected subgroups of patients
at the same institution. They also found that a low
serum albumin level was an independent predictor of
VTE in cirrhotic patients and that 79% of cirrhotic
patients received neither pharmacological nor mechani-
cal DVT prophylaxis, which is similar to the rate
observed in our study. Another case-control study by
Gulley et al. [7] found 1.8% incidence of VTE and the
risk for VTE was not lower than that determined for
matched non-cirrhotic controls without selected co-
morbidities, a finding similar to our study. Dabbagh
et al [14]. found an incidence of VTE of 6.3% in cirrho-
tic patients, and although the utilization of DVT pro-
phylaxis was suboptimal, there was no association
between the incidence of VTE and prophylaxis. The
high incidence of VTE could be explained by the greater
morbidity of these patients, as reflected by their high
child-Pugh scores. The failure of DVT prophylaxis
should be interpreted with caution, because the low
VTE incidence and low rate of DVT prophylaxis utiliza-
tion preclude the establishment of firm conclusions.
Our result and others [7,16,17] showed that the inci-
dence of VTE was not lower than that determined in
Table 3 The impact of VTE prophylaxis on the incidence of VTE in all hospitalized cirrhotic patients and subgroups of
hospitalized cirrhotic patients
DVT prophylaxis VTE 6 No VTE 220 OR(95%CI) P value
All Patients
Pharmacologic 1/6 (16.7%) 26/220 (11.8%) 1.49 (0.16-13.2) 0.54
Mechanical 2/6 (33.3%) 25/220 (11.9%) 3.9 (0.68-22.4) 0.15
None 3/6 (50%) 169/220 (78%) 0.28 (0.08-1.6) 0.13
Patients admitted with infections
Pharmacologic 1/2 (50%) 15/119(12.6%) 6.9 (0.41-116) 0.25
Mechanical 0/2(0%) 15/119 (12.6) 0.98 (0.96-100) 0.76
None 1/2 (50%) 89/119(74.8%) 0.31 (0.19-5.1) 0.42
Patients admitted with Bleeding
Pharmacologic 0/2(0%) 7/52 (13.5%) 0.96(0.9-1.02) 0.76
Mechanical 2/2(100%) 4/52 (7.71) 1.5 (0.85-2.6) 0.01
None 0/2(0%) 41/52(7.8-8.8%) NA 0.06
Patients with HCC
Pharmacologic 0/1(0%) 11/101 (10.9) NA 0.89
Mechanical 1/1(100%) 8/101(7.9%) 1.1 (2.9-1.4) 0.09
None 0/1(0%) 82/101(81%) NA 0.19
Patients with INR ≥ 1.8
Pharmacologic 0/1(0%) 0/1(0%) 0.98(0.93-1..03) 0.95
Mechanical 1/1 (100%) 7/40 (17.5%) 1.14(0.88-1.149) 0.19
None 0/1(0%) 31/40(77%) 0.89(0.7-1.12) 0.2
HCC: Hepatocellular carcinoma.
INR: international normalized ratio.
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cirrhosis of different etiologies and with varying levels of
severity.
Several mechanisms have been proposed to explain
the observed thrombosis in cirrhotic patients. An
acquired deficiency of antithrombotic III, protein C
and protein S and the presence of antiphospholipid
antibodies are observed in patients with cirrhosis
[5,18,19]. In addition to a decreased synthesis of antic-
oagulants, cirrhotic patients are prone to hypercoagula-
tion due to a chronic inflammatory state that results in
poor flow and vasculopathy [16,20]. Lisman et al [21]
found thrombin generation is equal or superior in
patients with liver cirrhosis undergoing liver transplan-
tation compared to healthy volunteers in the presence
of exogenous thrombomodulin. An imbalance between
the hemostatic process, thrombosis may produce a
prothrombotic state in which the risk of thrombosis is
increased [22]. Our study has several limitations that
are unavoidable in a retrospective study. It was con-
d u c t e di no n ec e n t e rw h e r et h es a m p l es i z ew a sr e l a -
tively small. In addition, some of the variables
extracted from the medical charts (such as patient life-
style) were not available, which could confound our
r e s u l t sa sw e l la st h es u s p e c t i n gP Ei sv e r yl o wa s
reflected by the fact that only one spiral CT of chest
was done. Despite these potential weaknesses, few stu-
dies have addressed this issue, and there are no guide-
lines regarding DVT prophylaxis in hospitalized
cirrhotic patients. The present study elucidates possible
predictors of the risk for VTE in this group of patients
and may aid in determining the patients who will ben-
efit from DVT prophylaxis, despite the notion that
auto-anticoagulation protects against VTE in cirrhotic
patients [17]. These data will pave the way for further
studies designed to evaluate the role of DVT prophy-
laxis in cirrhotic patients and alert healthcare providers
to consider VTE in the differential diagnosis of cirrho-
tic patients with coagulopathy when these patients
present with clinical features that are compatible
with VTE.
Until the risks and benefits of VTE prophylaxis are
established in this particular population, the VTE pro-
phylaxis can not be withdrawn in the cirrhotic popula-
tion at present time [23].
In conclusion, the incidence of VTE in hospitalized
cirrhotic patients was 2.7%, and the utilization of DVT
prophylaxis was suboptimal. Because the treatment and
prophylaxis for VTE carries an increased risk of bleed-
ing, additional prospective multicenter studies should be
conducted to address the benefits and risks of this
intervention.
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